Within the last decade, several studies have investigated whether adjuvant treatment of breast cancer affects cognitive function. A number of prospective studies have demonstrated inconsistent results regarding whether chemotherapy affects cognitive function. Approximately half of the studies demonstrated subtle cognitive decline in a wide range of domains among some breast cancer patients following chemotherapy, and half did not. Concomitant changes in brain structure and function have been identified in neuroimaging and neurophysiologic studies. Estrogenic therapy has been specifically associated with deterioration in verbal memory and processing speed. However, evidence is mostly based on smaller studies with cross-sectional data. Breast cancer patients who underwent both chemotherapy and estrogenic therapy showed the most deterioration and the most persistant decline in cognitive function. Since cognitive impairment is subtle, if evident at all, discrepant findings are due to hormonal, physiological, psychological or temporal confounding variables and differences in study design. Neuropsychological training has been demonstrated to improve cognitive dysfunction experienced by breast cancer patients after chemotherapy. Future research may examine the unique impact of endocrine therapy on cognitive function with prospective, controlled trials, as well as the role of further confounding variables (e.g., menopausal status, cytokine deregulation, cortisol and concurrent medication). †
Some evidence supports the notion that chemo therapy regimens pass the blood-brain bar rier [2] . Accordingly, treatment with chemo therapy may have some consequences for breast cancer patients' cognitive function (see Table 1 for a detailed description of observational stud ies on the effects of chemotherapy on cognitive function). The number of breast cancer patients affected by cognitive impairment in different studies reaches up to 61% [3, 4] , but most studies report that approximately 30% of patients expe rience subtle cognitive decline after treatment with chemotherapy [5] [6] [7] [8] [9] [10] .
Cognitive impairment has been found in multiple domains of cognitive function; many studies demonstrated longer reaction times [6, 11] and slower information processing [4] [5] [6] 9, 12, 13] in patients treated with chemotherapy. Furthermore, frequent domains of cognitive function affected by chemotherapy are working memory [9, [14] [15] [16] and verbal memory [5, 13, [16] [17] [18] . In addition, some studies also provide evidence of associa tions between chemotherapy and deteriorations in visuospatial memory [3, [12] [13] [14] 17, 19] , remote m emory [9] and attention [4, 12, 13] .
Breast cancer therapy consists of a combina tion of different treatment modalities, includ ing surgery, radiation, chemotherapy and hormonal therapy, which represent standard treatment options. These treatments involve a range of side effects affecting women's quality of life, with potential effects on body image, mood, the occurence of hot flashes and induced menopause being among those highly preva lent. Furthermore, consequences of breast can cer treatment on cognitive function have been reported. A growing body of research suggests that chemotherapy has an impact on cognitive function in some breast cancer patients. Since estrogen has neuroprotective effects [1] , endo crine therapy may influence cognitive function in addition to chemotherapy. Therefore, the present review will assess the consequences of breast cancer treatment on women's cognitive function, with a focus on the impact of chemo therapy and endocrine therapy, and is based on a literature search of PubMed and PsycInfo data bases (until January 2009) of published English language articles. Studies that described only subsamples of later studies have not been reported, so as not to bias the summary of results.
PersPective
Breast cancer treatment and cognitive function: the current state of evidence, underlying mechanisms and potential treatments No [5] One-arm; prospective Jansen et al.
Prior to AT; 1 week post-CT
BC patients
Simple Decreases in visuospatial skill and total cognitive scores following CT were found. Improvement in executive function was observed.
Yes [19] Three-arm; prospective No [20] One-arm; prospective On average, compromised cognitive function was evident in five out of 12 tests at baseline. CD was observed in 27% and improvement in 28% of patients over time.
No [8] Three-arm; prospective Bender et al. Comp CT + TAM group showed impairments in visual memory and verbal working memory. CT group showed deteriorations in verbal working memory only. Control group showed improvements suggestive of practice effects.
Yes [14] One-arm; prospective Hurria et al. Yes [9] Three-arm; prospective Jenkins et al. Age, education and intelligence predicted cognitive function across domains.
No [21] Four-arm; prospective Yes [22] One-arm; prospective Wefel et al. No [71] Two-arm; Simple A total of 33% of CT patients were cognitively impaired compared with 10% of healthy controls. After CMF, impaired women showed longer P3 latencies, lower P3 amplitudes, longer reaction times and made more errors in an information processing task compared with nonimpaired women after CMF.
cross-sectional
Yes [6] One-arm; Post-CT

BC patients
Simple Abnormal scores were observed on memory for 48%, language for 61% and visuospatial functioning for 33% of participants.
Yes [3] Three-arm; No [24] Three-arm; Yes [17] Two-arm;
cross-sectional
Tchen et al.
Post-CT 100 CT patients; 100 healthy controls Simple A total of 16% showed moderate-to-severe cognitive impairment versus 4% in controls.
Yes [72] Four-arm; Yes [18] Three-arm; 
PersPective -Vodermaier
A few studies have also shown a dose-response relationship with breast cancer patients treated with highdose chemotherapy demonstrat ing more severe cognitive impairment com pared with women treated with standarddose c hemotherapy [10, 12, 18] .
While most studies with a crosssectional design concluded that breast cancer patients who had undergone chemotherapy provided evidence of some degree of cognitive impair ment in different domains of functioning, the nine existing prospective studies provide a differ ent picture [4, 5, 8, 9, 14, [19] [20] [21] [22] . Of these, five studies reported overall decrements in cognitive func tion [4, 9, 14, 19, 22] . However, three [4, 9, 19] of these five studies are characterized as onearm trials with 30 participants or less. Four prospective studies did not provide evidence of overall cog nitive decline [8, 20, 23, 24] . Furthermore, four of the nine studies also reported improvement of cognitive functioning in some patients [4, 8, 14, 19] .
Several factors may explain these discrepant findings between crosssectional and prospec tive trials. Since some studies (see Table 2 ) suggest cognitive impairment even before commence ment of adjuvant therapy [11, 25] , the validity of crosssectional, as well as of longitudinal studies, is limited. Furthermore, discrepant treatment effects may also be due to subtle variations in sample composition and research design.
One possible explanation for decrements in objective cognitive function, even before com mencement of chemotherapy, could be a 'diag nostic shock' following a diagnosis of cancer. Several studies have shown that objective cogni tive function is not related to subjective cogni tive complaints. Objective cognitive function has been predicted by age, education and IQ [7, 21, 26] , whereas subjective cognitive function has been associated with negative affect and fatigue [17, 26] .
Study results are mixed regarding whether cognitive disturbances are transient [4, 5] or per manent [16, 21] . Although many recent studies are prospective in nature, they do not include a longterm followup and/or lack a control group of patients who did not undergo adju vant treatment or, alternatively, healthy controls. Hence, the strongest evidence can be derived from prospective studies with longterm follow up (>1 year after completion of treatment with chemotherapy) that include a control group of women with breast cancer who received local treatment only. While one of these highqual ity studies suggests no impact of chemotherapy on cognitive function [21] , other studies pro vide evidence of cognitive disruption as being Table 1 . Observational studies on chemotherapy and cognitive function (cont.).
Design
Author
Time point investigated
Patients
Measure Results
CD Ref.
Three-arm; Yes [73] Three-arm; Yes [12] One-arm; Breast cancer treatment & cognitive function -PersPective transient in nature [5] or demonstrate longterm persistence of cognitive decline in breast cancer patients treated with chemotherapy [14] . Hence, study results remain inconclusive at present as to whether cognitive disruption is transient or permanent. The majority of studies, if evident at all, suggest subtle impairment in cognitive functioning in a subgroup of breast cancer patients treated with chemotherapy. In order to determine whether cognitive dysfunction is a consequence of chemotherapy treatment that persists in breast cancer patients, studies also need to control for the effect of endocrine treat ment on cognitive function. Since many patients who have undergone chemotherapy usually con tinue with endocrine treatment for up to 5 years, interaction effects of chemotherapy and endo crine therapy need to be taken into account. Indeed, a few studies suggest that patients who had undergone both treatment modalities experienced the most pronounced cognitive dis ruption [5, 14, 17] , and the domains of cognitive impairment appear to be distinct to the type of endocrine therapy [27] . Therefore, future studies should control for hormonal treatment.
cross-sectional
Mechanisms
A number of studies have examined potential mechanisms by which treatment with chemo therapy may result in cognitive dysfunction. Among these are studies using electrophysiologi cal, neuroimaging and genetic techniques, as well as studies investigating immune responses. Eventrelated potential (ERP) studies asses sed during a cognitive task detected electro physiological alterations, such as reduced P3 latencies [28, 29] . Differences were also observed between patients treated with different chemo therapy regimens 3-6 years posttreatment [29] . The extent of alteration was related to the degree of cognitive disruption, although not all stud ies were confirmatory [30] . Longer P3 latencies have been demonstrated for simple and com plex cognitive tasks in patients who received treatment 5 years before the examination [30, 31] . Schagen and coauthors found no correlation between neurophysiologic parameters and neuro psychological performance, except for an overall relation between longer P300 latencies and the total number of deviant test scores [28] . Furthermore, asymmetry of the arhythm of 0.5 Hz or more was detected in seven patients treated with highdose chemotherapy, in two patients who had undergone standard chemo therapy and in none of the control patients. No differences were found between the groups with Patients with stages 1-3 BC had poorer than expected overall performance and longer reaction times than patients with stage 0 BC or healthy controls before initiation of AT. Correction for misclassification error: 22% (stages 1-3 BC) versus 0% (noninvasive) versus 4% (healthy controls) showed decrements in overall cognitive performance.
Yes [11] Two-arm;
cross-sectional
Debess et al. No [74] One-arm; with test performance, but distress was not.
No [26] Two-arm, prospective Yes [25] AT: Adjuvant treatment; BC: Breast cancer; CD: Cognitive decline; Comp: Comprehensive.
PersPective -Vodermaier regard to frequency of arhythm, ablocking or latency of P300. The absence of group dif ferences in N1 suggests that early perceptual processes are not affected by chemotherapy [29] .
Brain imaging studies conducted via func tional MRI during a shortterm recall task in breast cancer survivors 5-10 years after com pletion of chemotherapy demonstrated specific alterations in the activity of the frontal cor tex, the cerebellum and the basal ganglia [32] . However, effects on the basal ganglia were only evident in patients treated with both chemo therapy and tamoxifen (TAM). Positron emis sion tomo graphy imaging studies demonstrated lower resting brain metabolism and a larger area of frontal cortex activation in breast cancer patients treated with chemotherapy [32] .
White matter changes have been shown via structural MRI in women treated with high dose chemotherapy [33] . Furthermore, a twin case study indicated small differences in neuro psychological test performance but striking contrasts in selfreported cognitive complaints as well as structural and functional MRI dif ferences. Specifically, the twin who underwent chemo therapy had substantially more subjec tive cognitive complaints and more white mat ter hyperintensities on structural MRI. Using functional MRI, an expanded spatial extent of brain activation during working memory processing was found compared with the non affected twin [34] . This study suggests that chemo therapy may not only be related to abnor malities in brain structure, but also to abnor malities in brain functioning. Furthermore, after completion of treatment with chemotherapy, compensatory processes may occur since dif ferences in brain structure and functioning did not (or no longer) translate into discrepant neuropsychological performance.
Genetic investigations demonstrated that sur vivors with at least one e4 allele of the APOE gene scored significantly lower in visual memory and spatial ability domains, as well as tended to score lower in the psychomotor functioning domain when compared with survivors who did not carry an e4 allele of this gene [35] . The results of this study provide preliminary sup port for the hypo thesis that the e4 allele of the APOE gene may be a potential genetic marker for increased v ulnerability to chemotherapyinduced c ognitive decline.
Both cognitive dysfunction [11, 25] and elevated levels of proinflammatory cytokines [36, 37] have also been demonstrated in breast cancer patients before commencement of chemotherapy. Hence, cytokines released from tumor tissue might cause cognitive disorders before, during and after treat ment [38] . Consequently, cognitive changes may also occur by inflammation, and treatment with chemotherapy may add to c ognitive d ysfunction through different pathways.
Endocrine therapy & cognitive function
A large body of research suggests that estrogen increases neuroplasticity, enhances or main tains verbal memory and reduces the risk of Alzheimer's disease [39] . By contrast, results of the Women's Health Initiative Memory Study (WHIMS) examining the use of hormone replacement therapy (HRT) on cognitive func tion have been discouraging [40] and several theoretical and clinical issues with regard to the use and initiation of HRT have not yet been clarified [39] . In this trial women who underwent HRT performed worse in tests of cognitive func tion than participants who underwent natural menopause [40] . Derived from the WHIMS, the timing of HRT is considered critical for neuro protective effects leading to the 'critical period hypothesis'. This hypothesis suggests that the initiation of HRT should start around the time of the onset of menopause in order to display neuro protective effects, whereas the initiation of HRT after estrogen depletion would result in null or even detrimental effects on memory [1] .
In cancer patients, the effects of endocrine therapies on cognitive function have been stud ied to a lesser degree. Endocrine therapy for breast cancer includes treatment with selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs). TAM and raloxifene (RLX) rep resent common SERMs. Unlike estrogen, SERMs have estrogen agonist effects on some tissues and estrogen antagonist effects on other tissues. TAM has estrogen antagonist effects on the breast but estrogen agonist effects on other tissues, such as the endo metrium. The mode of action of TAM on the brain is not well understood.
Raloxifene is a drug that is not specifically for breast cancer patients but for postmenopausal women with osteoporosis. Similar to estro gen, RLX has agonist effects on bone and lipid metabolism, but estrogen antagonist effects on reproductive tissues. Hence, it does not increase the risk of breast and uterine cancer.
A second group of drugs, AIs, are used in post menopausal women with breast cancer. AIs rep resent newer agents of endocrine therapy. While TAM blocks receptors of female hormones, AIs prevent the transformation (aromatization) of androgens into estrogen. Yes [41] One-arm; prospective No [52] Three-arm; Yes [27] Two-arm; Yes [42] Three-arm, Yes [43] Two-arm; Yes [44] Two-arm, all postmenopausal Simple Little difference between women who had used TAM for the standard 5 years and never users on the three cognitive tests. However, more women who had used TAM for the standard term reported seeing their physician for memory problems than nonusers. This was especially true for current users of standardterm TAM. Current users also had a significantly lower mean complexity score on the narrative writing task. No differences were observed between past users and nonusers.
cross-sectional
Yes? [46] AC 
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Observational studies of endocrine therapies on cognitive function in patients with breast cancer are described in more detail in Table 3 . Effects of TAM on cognitive function have been investigated in seven studies, most of which were crosssectional and compared TAM users with AI users and/or healthy controls. Its use as an endocrine treatment for breast cancer has been associated with decrements in verbal mem ory [41] [42] [43] [44] [45] and processing speed [41, 44, 45 ]. An early study [46] demonstrated no differences between past users and never users of TAM, but current users were shown to attain a lower c omplexity score in a narrative writing task.
By contrast, another SERM, RLX has demon strated null [47] [48] [49] or small [50, 51] neuroprotective effects on the brain. In a large trial investigat ing treatment with RLX for 3 years, the drug was associated with reduced risk of cognitive impairment [51] .
Aromatase inhibitors have been compared with TAM in terms of their effects on cognitive function in four studies. Of these, one study sug gests that AIs have a comparable impact to TAM on cognition [44] , while Bender et al. reported poorer verbal and visual memory in AI users compared with TAM users [42] , and Schilder et al. found that TAM users fared worse in verbal functioning and AI users were slower on motor speed [27] . Concomitant lower plasma estrogen levels in women treated with AI compared with TAM could suggest a more profound effect of AI on cognitive function.
To date, only three prospective studies exam ining the effects of TAM and/or AI on cognitive function exist [41, 52, 53] . While Collins et al. found decrements in verbal memory and processing speed as well as in overall cognitive function ing in women with breast cancer treated with TAM or AI compared with healthy controls [41] , another study [52] found no effect of TAM or AI treatment on memory in women who had pre viously undergone neoadjuvant chemotherapy. However, this study did not include a com parison with groups of women with endocrine t reatment only or chemotherapy treatment only.
In contrast to the aforementioned studies, a doubleblind, placebocontrolled, randomized trial investigating AI versus placebo in postmeno pausal women at risk for breast cancer [53] did not demon strate differences in cognitive function for women treated with AI compared with placebo at 24month followup. While this study was not conducted in breast cancer patients, its signifi cance is based on a randomized, controlled trial design. Owing to the large sample size, it is not likely that an existing group difference could have been overlooked. In addition, confound ers, such as previous treatment with a different chemotherapy regimen or m enopausal status, were excluded.
Other hormonal agents, such as analogs of gonadotropinreleasing hormone, have not been investigated for their impact on cognitive function. These drugs (e.g., goserelin) are used in premeno pausal women with breast cancer to ablate ovar ian function. However, a few studies in healthy women suggest that cognitive function might not be affected by usage of g onadotropinreleasing hormone [54] [55] [56] .
Mechanisms
A few studies have examined the potential mech anisms of SERMs on brain function using MRI and positron emission tomography methods. Two studies compared three groups of postmeno pausal women, women who had received either TAM, estrogen or neither [43, 57] . Ernst and co authors found that the groups treated with TAM or estrogen both showed lower concentrations on one of four metabolites in the basal ganglia [57] . The authors, therefore, concluded that TAM has similar effects to estrogen. By contrast, Eberling et al. demonstrated TAM users to have wide spread hypometabolism in the interior, dorsal lateral and frontal lobes as well as smaller right and left hippocampal volumes [43] . Hippocampal volumes of women using neither TAM nor estro gen were intermediate to the two other groups. Nonusers also demonstrated lower metabolism in the inferior frontal and temporal cortexes com pared with the estrogen users. Consequently, the two studies provide conflicting results. While one study [57] concludes that TAM has a similar effect to estrogen on brain metabolism, the other [43] showed effects of TAM that were distinct from estrogen users and nonusers. An animal study of ovarectomized rats investigat ing the effects of different SERMs and estrogen on hippocampal neurons found SERMs to have different dosedependent neuroprotective effects that were distinct from estradiol [58] , support ing the Eberling et al. findings in humans [43] . Differential effects of specific SERMs on brain function in an animal study [58] also correspond to neuropsychological findings suggesting that TAM probably has detrimental effects, whereas RLX probably has slightly favorable effects on some aspects of cognitive function.
Distinct effects of AIs on brain function have not been studied as yet. To conclude, mecha nisms of estrogenic therapy for breast cancer on brain function have been scarcely studied and it remains to be clarified in what respect their effects are distinct versus comparable to the use of HRT.
Treatment of cognitive function
A few drugs as well as psychological interventions have been investigated to prevent cognitive decline in breast cancer patients (who were treated with chemotherapy). While one study suggests that erytropoetin, a drug for the prevention and treat ment of anemia and fatigue in cancer patients, may have attenuated the cognitive impairment and fatigue that occurred during adjuvant breast cancer chemotherapy [59] , in another study, no effect of this drug on cognitive function was observed [60] . In addition, methylphenidate, a CNS stimulant approved for attentiondeficit/ hyperactivity disorder and narcolepsy, did not show beneficial effects on memory [61] . A recent study demonstrated that modafinil, a drug used to treat sleep apnea, modestly improved shortterm memory in breast c ancer patients [62] .
By contrast, behavioral interventions appear to have more potential to improve cognitive dysfunction in breast cancer patients who have undergone chemotherapy. Neuropsychological training, so called Memory and Attention Adaptation Training (MAAT), demonstrated improvements in objective measures of cogni tive function and also improved stress man agement in dealing with memory problems in everyday life at 2 and 6month followup [63] . The MAAT consists of a participant workbook, four individual monthly visits of 30-50 min and phone contacts between visits. The four c ognitive-behavioral components include:
• Education on memory and attention;
• Selfawareness training;
• Selfregulation emphasizing arousal reduction through relaxation training, activity s chedu ling and pacing;
• Training of cognitive compensatory strategies.
The application of strategies was considered the homework between visits. The telephone contacts were intended to assist in applying the strategies.
With regard to the inhibition of mechanisms contributing to inflammation, a randomized, controlled trial using cognitive-behavioral stress management demonstrated increased benefit finding and reduced cortisol levels. Effects on cor tisol were mediated by benefit finding [64] . A dif ferent trial demonstrated improved lymphocyte proliferation under the same treatment condi tion [65] . Neurodamaging effects of stress and inflammation have been indicated in a number of studies [66] [67] [68] . Hence, behavioral interventions that usually target other goals may also prevent cognitive impairment in breast c ancer patients.
Future perspective
Considering the inconsistent findings with regard to cognitive dysfunction due to treat ment with chemotherapy, the characterization of subgroups at risk for cognitive decline would be an important target for future research. The identification of vulnerable subgroups would allow an early intervention targeted at maintain ing cognitive function in these patients. Looking at studies that demonstrated neurophysiologic compensation [34] , it can be assumed that pre vention of cognitive impairment may be pos sible. As neuro psychological training and stress management techniques have been effective in reversing cognitive decline, its preventive and rehabilitative application could have some merit for clinical practice.
Otherwise, in cases where reasonable choices exist between different chemotherapy regimens, there could be a preference to opt for the less aggressive regimen since evidence suggests a dose-response relationship with women treated with highdose chemotherapy, demonstrating more pronounced cognitive symptoms com pared with patients treated with standarddose chemotherapy [10, 12, 18] . However, decision mak ing in this regard should be carried out fol lowing extended counseling of the patient that allows her to weigh the pros and cons of each decisional option.
Owing to the fact that results on chemo therapyrelated cognitive dysfunction were dis crepant regarding whether they are transient or persistent, future studies should include longer followup to more thoroughly address this issue.
Several biological mechanisms have been identified that may underlie cognitive decline in breast cancer survivors treated with chemo therapy. If cognitive changes were transient in nature, it would be interesting to see whether biological alterations would also improve, or, in cases where neurophysiologic compensation is occurring, whether these effects are also associ ated with improvements in cognitive function assessed by neuropsychological testing.
Endocrine therapy has been demonstrated to have detrimental effects on cognitive function, specifically with regard to verbal memory and processing speed in most studies. However, these PersPective -Vodermaier studies were mostly crosssectional and one of the three prospective studies is a secondary data ana lysis of breast cancer patients that received prior treatment with chemotherapy [52] . Collins and co authors found that postmenopausal women with breast cancer treated with TAM or AI demon strated lower scores on verbal memory, process ing speed and overall cognitive functioning com pared with healthy controls [41] . By contrast, the International Breast Cancer Intervention Study (IBIS)II trial [53] , a doubleblind, randomized, controlled trial with a large sample of women at high risk for breast cancer, found no detrimental effect of AI on cognitive function.
While the results of the two latter studies are conflicting, both studies are free of some major confounds, such as pretreatment with chemotherapy and mixed menopausal status. Consequently, effects of endocrine treatment on cognitive function need to be studied with more robust research designs, such as prospec tive trials with larger sample sizes controlling for major confounds (e.g., chemo therapy pretreat ment, hormonereplacement pretreatment and m enopausal status).
In some studies, patients treated with endo crine therapy in addition to chemotherapy per formed worse cognitively compared with breast cancer patients treated with chemotherapy alone, or the detrimental effects on cognition were more permanent than in patients treated with chemotherapy alone [5, 14, 17] . These findings may support the argument for a shared vulner ability of some women who experience cogni tive decline as a consequence of chemotherapy and/or endocrine therapy.
Little is known about whether menopausal status of patients affects the extent to which breast cancer patients experience cognitive decline in response to adjuvant treatment. Several studies were com pleted in postmenopausal women. Nevertheless, most research was conducted on samples of both pre and postmenopausal women and, in most studies, a significant proportion of postmeno pausal patients at some point underwent HRT. However, the small sample sizes of most existing controlled, prospective trials deal with problems of statistical power and hence may not reliably detect significant moderator effects. While early estrogen deprivation in premenopausal women may have more profound effects on longterm cognitive function compared with older women, the latter group's potential for compensation of cognitive dysfunction may be less likely since estrogen deprivation is ongoing after completion of adjuvant treatment. Similarly, with regard to the effects of chemotherapy on cognitive function, a higher potential for compensation in younger women may be assumed. Furthermore, few stud ies have included data on the effects of treatment induced menopause on cognitive function [21, 52] and their results are inconsistent. In addition, evidence from noncancer samples is inconclu sive regarding whether induced m enopause has d etrimental effects on cognition [69] .
Limitations of prior research include several methodological issues. The majority of existing research is based on a comprehensive assessment of cognitive function with a wide set of neuro psychological tests. The use of less sophisticated assessments captures the risk of low sensitivity to detect cognitive decline. Therefore, the use of the highsensitivity cognitive screen appears to be inappropriate to measure cognitive function in breast cancer patients, since the instrument may not capture subtle c ognitive decline [3] .
Furthermore, meaningful results can only be drawn from prospective studies that contain a baseline assessment of cognitive function and include a control group. The choice of a control group of breast cancer patients who only received local treatment has the advantage that women across groups share the experience of a cancer diagnosis with its emotional turmoil and poten tial effects on cognition (since some studies [11, 25] reported cognitive dysfunction even before com mencement of adjuvant therapy). However, this choice of a control group may also represent patients with a better prognosis and better physi cal health. In addition, treatment of breast can cer is becoming more and more individualized, which makes the control of a myriad of potential confounds a challenge. For example, the use of antibody therapy has not been studied so far in terms of its consequences on cognitive function.
Findings concerning the effects of endocrine treatment on cognitive function suggest that breast cancer patients undergoing endocrine therapy also do not appear to represent an appro priate control group to examine the effects of chemotherapy on cognitive function.
Several studies used a matched comparison group of healthy women as a control group. This choice of control group does not account for illnessrelated confounds and hence, prefer ably, should be included in addition to a dis ease control group. Nonetheless, the inclusion of a healthy control group holds the possibility to account for practice effects or normal aging (for longer time intervals) as well as the possi bility of heightening the sensitivity of the mea surement of change in cognitive function [70] .
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Ouimet and coauthors suggest a standardized regressionbased approach for individualbased analyses [70] . This method uses change scores of a matched control group of healthy individuals to account for practice effects in order to more reli ably measure cognitive change in patients with breast cancer. This method has been shown to be more sensitive compared with group analyses and the reliable change index method [70] .
No studies to date have investigated whether newer moleculartargeted therapies of breast can cer (e.g., trastuzumab) impact cognitive function
Executive summary
Chemotherapy & cognitive function • Half of the published prospective trials support the assumption that subtle cognitive decline in multiple domains of cognitive function occurs in some breast cancer patients, whereas other prospective studies have not demonstrated cognitive impairment following chemotherapy. • A few studies suggest a dose-response relationship with patients treated with high-dose chemotherapy experiencing a more pronounced cognitive dysfunction compared with standard-dose chemotherapy. • Some patients showed cognitive decline before initiation of adjuvant treatment.
• Results regarding whether cognitive alterations are transient or permanent are inconsistent.
• Cognitive impairment is correlated with age, education and IQ. Subjective cognitive complaints are not associated with objective cognitive function.
Mechanisms of chemotherapy-induced cognitive dysfunction
• Some evidence supports the notion that chemotherapy regimens pass the blood-brain barrier.
• A direct neurotoxic effect may lead to atrophy of cerebral grey and white matter.
• Long-term alterations in the activity of the frontal cortex, the cerebellum and basal ganglia have been shown in breast cancer patients after treatment with chemotherapy. • Breast cancer patients treated with chemotherapy demonstrated long-term lower resting brain metabolism compared with breast cancer patients who had never been treated with chemotherapy. • e4 allele of APOE as a potential genetic risk marker for increased vulnerability to chemotherapy-induced cognitive decline.
Endocrine therapy & cognitive function
• Cross-sectional studies suggest cognitive impairment specifically in verbal memory and processing speed in women treated with tamoxifen or aromatase inhibitors. • The scarce prospective data are inconsistent. The International Breast Cancer Intervention Study (IBIS)-II, a double-blind, randomized, controlled trial in women at risk of breast cancer, did not show cognitive dysfunction in the aromatase inhibitor group compared with the control group.
Mechanisms of estrogenic therapy-induced cognitive dysfunction
• Tamoxifen users have shown hypometabolism in the inferior and dorsal lateral frontal lobes and smaller hypocampal volumes. However, it remains to be clarified whether the effects are distinct for tamoxifen or are similar to the effects of estrogen on brain function. • The effects of aromatase inhibitors on brain function are unknown at present.
Treatment
• Neuropsychological training (using Memory and Attention Adaptation Training, a manual-based, structured intervention) demonstrated improvements in objective measures of cognitive function. • Cognitive-behavioral stress management demonstrated reductions in cortisol levels, a potential mediator of cognitive dysfunction.
• No approved drugs are available at present.
Future perspective
• Future research may examine the unique impact of endocrine therapy on cancer therapy-related cognitive change with prospective, controlled trials. • Identification and characterization of vulnerable subgroups for cancer therapy-related cognitive change, as well as which patients have the potential to compensate for cognitive impairment would be useful in the future. • Potential confounders that should be controlled in future studies are menopausal status/induced menopause, concurrent medication (affecting the CNS), distress, fatique, change in symptom severity over time, cytokine dysregulation and cortisol. • In terms of potential moderators of cognitive dysfunction, the examination of the role of stress and inflammation on cognitive outcomes in breast cancer survivors merits further empirical attention. • Testing of the efficacy of neuropsychological training and its potential for compensation should be conducted.
• Exploration of the effects of analogs of gonadotropin-releasing hormone (e.g., goserelin) and molecular-targeted therapies for breast cancer (e.g., trastuzumab) on cognitive function should be carried out. • Alternative models of cancer therapy-related cognitive change (since some patients showed cognitive dysfunction before commencement of adjuvant therapy) should be studied.
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of breast cancer survivors in the long term. Future research may address their impact on cogni tive function or at least control their effects as moderators of traditional cancer t reatment on c ognitive function.
In conclusion, owing to the mixed and con flicting findings, it is not yet clear whether adju vant treatment of breast cancer is associated with cognitive impairment. Since some cancer patients show cognitive compromise even before initiation of adjuvant treatment, other unknown factors may contribute to the phenomenon of cognitive change associated with breast cancer therapy. For example, some vulnerable patients may experience prolonged or more pronounced effects of anesthe sia following breast surgery. The stress response resulting from a recent cancer diagnosis may also prevent some new patients from fully engaging and performing well in c ognitive assessments.
Breast cancer patients' quality of life is com promised for a significant time during and even sometimes after completion of chemotherapy.
The reduced physical health as a consequence of chemotherapy may impact cognitive function, although fatigue has been repeatedly shown not to be associated with 'chemo brain'.
Future research should further investigate the role of estrogenic therapy for the phenomenon of breast cancer therapyassociated cognitive change as well as the fact that some patients demon strate transient cognitive impairment while others report longterm consequences.
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